Company Encyclopedia
View More
name
ZHIFEI-BIOL
300122.SZ
Chongqing Zhifei Biological Products Co., Ltd. engages in the research and development, production, marketing, distribution, import, and export of vaccines in China. The company offers Recombinant Novel Coronavirus Vaccine (CHO Cell); Recombinant Mycobacterium Tuberculosis Fusion Protein under the Ekear brand; Haemophilus Influenzae Type b Vaccine under the XiFeiBei brand; ACYW135 Meningococcal Polysaccharide Vaccine under the Menwayc brand; Mycobacterium Vaccae for Injection under the Vaccae brand; Meningococcal Group A and Group C Polysaccharide Conjugate Vaccine under the Mening A Con brand; and other developed products. It also provides cold storage services.
1.555 T
300122.SZMarket value -Rank by Market Cap -/-

Financial Score

25/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking62/81
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-4.31%D
    • Profit Margin-12.00%D
    • Gross Margin18.07%D
  • Growth ScoreE
    • Revenue YoY-70.05%E
    • Net Profit YoY-135.77%E
    • Total Assets YoY-13.62%E
    • Net Assets YoY-5.84%D
  • Cash ScoreE
    • Cash Flow Margin-833.08%E
    • OCF YoY-70.05%E
  • Operating ScoreD
    • Turnover0.22D
  • Debt ScoreB
    • Gearing Ratio36.18%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    ZHIFEI-BIOL released its performance for the first three quarters, with a net loss attributable to the parent company of 1.206 billion yuan

    According to the Zhitong Finance APP, ZHIFEI-BIOL released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 7.627 billion yuan, a year-on-year decrease of 66.53%. The net loss attributable to shareholders of the listed company was 1.206 billion yuan. The net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 1.227 billion yuan. The basic loss per share was 0.504 yuan

    Zhitong·
    SZ
    300122
    +0.83%
    Zhitong·
    SZ
    300122
    +0.83%

    ZHIFEI-BIOL: The company's self-developed influenza virus split vaccine has obtained a drug registration certificate

    ZHIFEI-BIOL's wholly-owned subsidiary ZHIFEI Longke Ma has developed a split influenza virus vaccine that has received the drug registration certificate from the National Medical Products Administration. This vaccine is suitable for individuals aged 32 and above and is used to prevent infectious diseases caused by the influenza virus. It is one of the main products for influenza prevention both domestically and internationally. The registered trivalent influenza vaccine, along with the quadrivalent influenza vaccine already approved by the company and other products under research, forms a rich series of influenza vaccines

    Zhitong·
    SZ
    300122
    +0.83%
    Zhitong·
    SZ
    300122
    +0.83%

    ZHIFEI-BIOL: CA111 injection has received approval for clinical trials

    ZHIFEI-BIOL's subsidiary, Chen'an Biotech, has received clinical trial approval from the National Medical Products Administration for its CA111 injection, allowing trials to be conducted in overweight or obese adult patients. CA111 is a dual agonist that targets GIP and GLP-1 receptors, aimed at improving blood glucose control and weight loss through a synergistic mechanism

    Zhitong·
    SZ
    300122
    +0.83%
    Zhitong·
    SZ
    300122
    +0.83%

    A-share innovative drug concept stocks fluctuated upward, EASTON BIOPHARMACEUTICALS and BioKangtai rose over 10%, Thalys, Staidson BioPharm, ALK, and ZHIFEI-BIOL followed suit

    Zhitong·
    SZ
    300122
    +0.83%
    SH
    688513
    +1.92%
    SH
    603716
    -1.73%
    Zhitong·
    SZ
    300122
    +0.83%
    SH
    688513
    +1.92%
    SH
    603716
    -1.73%

    ZHIFEI-BIOL: The company's application for clinical trials of the acellular DTP (component) combined vaccine (for adults and adolescents) has been accepted

    Wallstreetcn·
    SZ
    300122
    +0.83%
    Wallstreetcn·
    SZ
    300122
    +0.83%
    © 2025 Longbridge｜Disclaimer